This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
NIHR HSRIC. Ticagrelor (Brilique) for preventing thombotic events in patients with acute ischaemic stroke or high risk transient ischaemic attack. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015
Ticagrelor is an oral, reversibly bound antagonist of the P2Y₁₂ adenosine diphosphate receptor, which inhibits platelet aggregation. Ticagrelor belongs to a class of drugs called cyclopentyltriazolopyrimidine inhibitors, which bind directly to the P2Y₁₂ receptor without conversion to an active metabolite. This allows a rapid onset of action. Ticagrelor is intended to prevent thrombotic events in patients with acute ischaemic stroke or high risk transient ischaemic attack (TIA). Ticagrelor is administered at a dose of 90mg twice daily, following a single 180mg loading dose. It is currently licensed in combination with aspirin for the prevention of atherothrombotic events in patients with acute coronary syndrome.
Stroke affects between 174 and 216 people per 100,000 population in the UK each year and accounts for about 11% of all deaths in England and Wales. An estimated 85% of strokes are due to ischaemic stroke, 10% to primary haemorrhage and 5% to subarachnoid haemorrhage. The risk of recurrent stroke within 5 and 10 years of the initial event is 26% and 39%, respectively. TIA affects about 35 people per 100,000 population each year and is associated with a high risk of stroke in the first month after the event and up to one year afterwards.
Current treatment for patients following ischaemic stroke or TIA includes medications such as anticoagulants, antiplatelets, statins and thrombolytic agents. Surgery is also an option for some patients. Ticagrelor is currently in a phase III clinical trial investigating its effects on reducing subsequent vascular events as compared to aspirin. Results from this trial are expected in 2016.
Subject indexing assigned by CRD
Adenosine; Humans; Ischemic Attack, Transient; Risk; Stroke
Country of organisation
An English language summary is available.
Address for correspondence
NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: firstname.lastname@example.org
Date abstract record published